by British Medical Journal Credit: CC0 Public DomainMany cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ. Despite pharmaceutical industry claims that high drug prices are needed to offset research and development...